Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc.

FENC·NASDAQ

$9.35

-6.3%
HealthcareBiotechnology

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

At a Glance

Live Snapshot
Market Cap$267.13M
EPS-0.3600
P/E Ratio-25.96
Earnings Date08/13/2026

fenc

Other Current Liabilities

Last Annual Value

5.62M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

53%

Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. Competitors Analysis of Other Current Liabilities

FENC · NASDAQ
CompanyOther Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
5.62M
N/AN/A67.2% 
9.89M
54.9%66.2%N/A
15.15M
N/AN/AN/A
10.14M
106.9%9.5%N/A
8.13M
27.9%22.8%N/A
3.52M
31.9%16.4%5.8%
3.71M
88.3%82.2%N/A
17.68M
32.1%31.1%N/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
12.41M
117.8%114.7%N/A
16.54M
15.9%28.3%N/A
9.50M
-44.7%N/A14.9%
Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. Fair Value Envelope

FENC · NASDAQ

Our analysis suggests that FENC has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.3467, this represents a potential HIDDEN relative to our calculated worth for Fennec Pharmaceuticals Inc..

Intrinsic Value
Current Price: $9.3467